Bausch's OraPharma expands into Canada, Puerto Rico

Mr. Tom Stern reports BAUSCH HEALTH'S ORAPHARMA EXPANDS INTO CANADA AND PUERTO RICO, HELPING TO ADDRESS UNMET NEEDS IN PERIODONTAL DISEASE Bausch Health Companies Inc.'s OraPharma has expanded commercially into Canada and Puerto Rico. This strategic move reflects OraPharma's commitment to improving oral health awareness, providing access to treatments within periodontal disease management and strengthening partnerships with local distributors and dental professionals in these markets. Periodontal disease continues to be one of the most prevalent chronic oral conditions worldwide. Findings from the Global Burden of Disease Study (2021) reveal that over one billion people are affected globally. In Canada, the Canadian Dental Association estimates that seven in 10 Canadians will develop gum disease during their lifetime. In Puerto Rico, 44.5 per cent of older adults are living with moderate to severe periodontal disease. These figures highlight the urgent need for greater awareness and improved access to treatment options. For more than two decades, OraPharma has been dedicated to helping advance periodontal care. Its flagship product, Arestin, is the only Food and Drug Administration-(FDA)-approved locally applied antibiotic for use with scaling and root planing (SRP) as part of periodontal disease management and is supported by over 20 years of clinical experience. Arestin is indicated as an adjunct to SRP for pocket depth reduction in adult periodontitis, helping dental professionals in delivering comprehensive care. This expansion into Canada and Puerto Rico is intended to improve access to periodontal care in these areas. "OraPharma remains committed to addressing periodontal disease, a condition that affects more than 1 billion globally," said Tom Stern, vice-president and general manager, OraPharma, Bausch Health. "By expanding access to Arestin in Canada and Puerto Rico, we aim to help address the gaps in care and provide dental professionals with a treatment option to support improved oral health for their adult periodontitis patients." What is Arestin? Arestin (minocycline HCl) Microspheres, one milligram, is used in combination with scaling and root planing (SRP) procedures to treat patients with adult periodontitis (gum disease). Arestin may be used as part of an overall oral health program that includes good brushing and flossing habits and SRP. Important safety information Do not use Arestin if you are allergic to minocycline or tetracyclines, ask your dentist if you are not sure. Do not use Arestin in children, pregnant or nursing women as the use of tetracycline class drugs, including Arestin, during tooth development may cause permanent discoloration of the teeth. Arestin may cause you to be sensitive to sunlight. Patients exposed to direct sunlight or ultraviolet light may develop a severe sunburn. At the first evidence of skin redness, call your dentist. Serious allergic reactions have occurred with oral minocycline. Get emergency help right away if you experience any signs of an allergic reaction including shortness of breath, swelling of the face, throat and tongue, rash, hives, itching, fever, or enlarged lymph nodes. Tetracyclines, including oral minocycline, have been associated with the development of autoimmune syndromes with symptoms such as joint pain, muscle pain, rash, swelling, fever, enlarged lymph nodes and general body weakness. Tell your dentist about all the medicines you take and about any health problems you have, including if you have had oral candidiasis (thrush). Arestin has not been studied in patients with weakened immune systems, such as patients with HIV infections or diabetes, or those receiving chemotherapy or radiation. The most frequently reported non-dental side effects were headache, infection, flu symptoms and pain. You are encouraged to report negative side effects of prescription drugs to the FDA. About Bausch Health Companies Inc. Bausch Health Companies is a global, diversified pharmaceutical company enriching lives through its relentless drive to deliver better health care outcomes. The company develops, manufactures and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through the company's controlling interest in Bausch + Lomb Corp. The company's ambition is to be a globally integrated health care company, trusted and valued by patients, HCPs, employees and investors. OraPharma is a specialty pharmaceutical company committed to partnering with dental professionals to improve oral health. We seek Safe Harbor.